IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Graeme Semple, et al.	Art Unit	: Unknown
Serial No.	: 10/560,332	Examiner	: Unknown
Filed	: December 9, 2005	Conf. No.	: 9629
Title	: 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV828220079US, EV664068355US, EV213533471US

February 22, 2007
Date of Deposit

Respectfully submitted,

Date: February 22, 2007

Christine A. Goddard, Ph.D.
Reg. No. 46,731

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21561054.doc

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEB 2 2 2007

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number Number - Kind Code[2] (*if known*)	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2005/0143443 A1	06-30-2005	Fang *et al.*,	
	AB	US-2004/0220186 A1	11-04-2004	Bell *et al.*,	
	AC	US-2002/0103215 A1	08-01-2002	Gurram *et al.*,	
	AD	US-6,200,980 B1	03-13-2001	Piazza *et al.*,	
	AE	US- 5,846,990	12-08-1999	Murugesan *et al.*,	
	AF	US-5,464,860	11-07-1995	Lepage *et al.*,	
	AG	US-4,282,361	08-04-1981	Hecht *et al.*,	
	AH	US-4,238,506	12-09-1980	Stach, deceased *et al.*,	
	AI	US-3,980,646	09-14-1976	Brenner *et al.*,	
	AJ	US-3,637,714	01-25-1972	Carlsson *et al.*,	
	AK	US-2005/154024	07-14-2005	Bryans *et al.*,	
	AL	US-2005/182108	08-18-2005	Carson *et al.*,	
	AM	US-6,444,816 B1	09-03-2002	Das *et al.*,	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AN	WO 2004/085401 A1	10-07-2004	Pfizer		
	AO	WO 2004/078732 A1	09-16-2004	Aventis Pharma S.A.		
	AP	WO 2004/026829 A2	04-01-2004	Boehringer Ingelheim Pharma GMBH & CO. KG		
	AQ	WO 03/037899 A1	05-08-2004	Pfizer		
	AR	WO 03/037432 A1	05-08-2003	Pfizer Products Inc.		
	AS	WO 03/035065 A1	05-01-2003	Aventis Pharma Inc.		
	AT	WO 03/033484 A1	04-24-2003	Bayer Aktiengesellschaft		
	AU	WO 02/062799 A1	08-15-2002	Dr. Reddy's Research Foundation		
	AV	WO 99/54333 A1	10-28-1999	Pfizer Limited		
	AW	WO 98/49166 A1	11-05-1998	Pfizer		
	AX	WO 97/29748 A1	08-21-97	Bristol-Myers Squibb Company		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

OIPE
FEB 2 2 2007
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AY	WO 02/50091 A1	06-27-2002	Glaxo Group Limited		
	AZ	WO 02/10171 A1	02-07-2002	Pfizer		
	BA	WO 01/55136 A1	08-02-2001	Syngenta Limited		
	BB	WO 01/49689 A2	07-12-2001	Warner-Lambert Company		
	BC	JP 2004168706 A	06-17-2004	Nissan Chem Ind Ltd.		
	BD	WO 01/27113 A2	04-19-2001	Pfizer		
	BE	WO 01/27101 A2	04-19-2001	Pfizer		
	BF	WO 01/02369 A2	01-11-2001	Agouron Pharma Inc.		
	BG	JP 2004217553 A	08-05-2004	Nissan Chem Ind LTD		
	BH	JP 57106665 A	07-02-1982	Showa Denko KK		
	BI	JP 02129171 A	05-17-1990	Nissan Chem Ind Ltd		
	BJ	EP 1475094 A1	11-10-2004	Ustav Experimentalni Botaniky Akademie ved Ceske Republiky		
	BK	EP 1348707 A1	10-01-2003	Ustav Experimentalni Botaniky Akademie ved Ceske Republiky		
	BL	EP 1176142 A1	01-30-2002	Pfizer		
	BM	EP 1092720 B1	01-12-2005	Pfizer		
	BN	EP 0995750 A1	04-26-2000	Pfizer		
	BO	EP 0994115 B1	03-02-2005	Pfizer		
	BP	EP 0562833 A1	03-23-1993	Sankyo Company Limited		
	BQ	EP 0463756 B1	06-07-1991	Pfizer		
	BR	EP 0459887 A1	05-28-1991	Novapharme		
	BS	EP 0442430 B1	02-11-1991	Lonza AG		
	BT	EP 0029364 A1	11-14-1980	Morishita Pharma Co. LTD.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

OIPE
FEB 2 2 2007
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BU	EP 0029363 A1	11-14-1980	Morishita Pharma Co. LTD.		
	BV	DE 2604560 A1	08-11-1977	Boehringer Mannheim GmbH		
	BW	DE 2559655 A1	06-02-1977	Fa. Johann A. Wulfing		
	BX	DE 2512886 A1	09-30-1976	Fa. Johann A. Wulfing		
	BY	WO 2003/032928 A1	04-22-2004	Arena Pharmaceuticals, Inc.		
	BZ	GB 1048104	11-09-1966	The Upjohn Company		
	CA	JP 54014968	02-03-1979	Taiho Pharmaceutical Co. Ltd.		
	CB	WO2004/054974	07-01-2004	SmithKline Beecham Corporation		
	CC	WO2005/009965	02-03-2005	Pfizer Ltd.		
	CD	WO2005/084663	09-15-2005	Janssen Pharmaceutica		
	CE	WO2006/023750	03-02-2006	Merck & Co., Inc.		
	CF	WO2006/032519	03-30-2006	Hoffmann-La Roche		
	CG	WO2006/032851	03-30-2006	Biolipox AB		
	CH	WO2006/032852	03-30-2006	Biolipox AB		
	CI	WO2006/052569	05-18-2006	Arena Pharmaceuticals, Inc.		
	CJ	DE 2454137 A1	05-20-1976	Fa. Johann A. Wulfing		
	CK	WO03/000659	01-03-2003	Nissan Chemical Industries		
	CL	WO02/22601	03-21-2002	Vertex Pharmaceuticals, Inc.		
	CM	WO00/69849	11-23-2000	Ortho-McNeil Pharmaceutical, Inc.		
	CN	WO03/099793	12-04-2003	Takeda Chemical Industries, Ltd.		
	CO	WO2004/033431	04-22-2004	Arena Pharmaceuticals, Inc.		
	CP	HU184940B	11-28-1984	Gyogyszerkutato Intezet		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 4 | of | 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

OIPE IAP91 FEB 2 2 2007 PATENT & TRADEMARK OFFICE

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	CQ	HANING *et al.*, "Comparision of Different heterocyclic scaffolds as substrate analog PDE5 inhibitors," *,Bioorganic & Medicinal Chemistry Letters*, (2005), 15(17), 3900-3907	
	CR	WIERZCHOWSKI *et al.*, "Analogues of Formycins A and B: Sythesis and Some Properties of Methyl Derivatives of 7-Amino and 7-Keto Pyrazolo (4,3-d) Pyrimidines," *,Acta Biochimica Polonica,* (1980), 27(1), 35-56	
	CS	WIPF *et al.*, "Metathesis Reactions of Pyrazolotriazinones Generate Dynamic Combinatorial Libraries," *Organic Letters,* (2005), 7(20), 4483-4486	
	CT	SIMENEL, "Erratum to 'Synthesis and enantiomeric resolution of ferrocenyl(alkyl)azoles'," *Journal of Organometallic Chemistry,* (2004), 689(3), 702	
	CU	WISE *et al.*, "Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid," *Journal of Biological Chemistry*, (2003), 278(11), 9869-9874	
	CV	SIMENEL *et al.*, "Synthesis and enatiomeric resolution of ferrocenyl(alkyl)azoles," *Journal of Organometallic Chemistry,* (2003), 688(1-2), 138-143	
	CW	FRENCH *et al.*, "Effects of nutritional status and acute variation in substrate supply of cardiac and skeletal-muscle fructose 2,6-bisphosphate concentrations," *Biochemical journal*, (1988), 250(3), 773-9	
	CX	HOLNESS *et al.*, "Regulation of renal and hepatic pyruvate dehydrogenase complex on carbohydrate re-feeding after starvation," *Biochemical journal*, (1987), 241(2), 421-5	
	CY	HOLNESS *et al.*, "Effects of Administration of tri-iodothyronine on the response of cadiac and renal ryruvate dehydrogenase complex to starvation for 48 h," *Biochemical journal,* (1985), 232(1), 255-9	
	CZ	SUGDEN *et al.*, " Effects of adrenaline on ketogenesis from long-and medium-chain fatty acids in starved rats," *The Biochemical journal*, (1982), 204(3), 749-56	
	DA	STEINFELDER *et al.*, "In Vitro Effetcs of Theophylline on Insulin Receptors in Adipocytes: Correlation with the Lipolytic action of the Agent," *Biochemical and biophysical research communications,*(1982), 104(1), 45-51	
	DB	McALLISTER *et al.*, "The Effect of 5-Methylpyrazole-3-Carboxylate and Nicotinic Acid on Abnormalities of Carbohydrate Metabolism in Alloxan-Diabetic Rat Muscle,"*Biochemical Pharmacology,* (1982), 31(1), 63-8	
	DC	CREDNER *et al.*, "Salze der 5-Methylpyrazol-3-carbonsaure mit basisch substituierten Adenin-Derrivaten,",*Arzneimittel-Forschung*, (1981), 31(12), 2096-100	
	DD	PODDAR *et al.*, "Potentiometric Investigation of Complex Equilibria Involving 5(3)- Methylpyrazole-3 (5)-carboxylic Acid with Some Metal Ions in Aqueous Solution," *Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical*, (1979), 18A(3), 252-4	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

FEB 2 2 2007

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	DE	GRIMMETT *et al.*, "The *N*-Alkylation and *N*-Arylation of Unsymmetrical Pyrazoles," *Australian Journal of Chemistry, (*1979), 32(10), 2203-13	
	DF	LEWIS *et al.*, "Synthesis of Pyrazolo (4,3-d) Pyrimidines via the Versatile Intermediate Ethyl 3-Methl-4-nitropyrazole-5-carboxylate," *Nucleic Acid Chem.*, (1978), 1, 121-8	
	DG	ROSAK *et al.*, "Chracterization of Lipolytic Responses of Isolated White Adipocytes from Hamsters," *Biochimica et Biophysica Acta*, General Subjects (1977), 496(2), 458-74	
	DH	BIEROWSKA-CHARYTONOWICZ *et al.*, "Search for New Aminoguanidine Derivatives with Immunosuppressive and Cytostatic Properties," *Archivum Immunologiae et Therapiae Experimentalis*, (1976), 24(6), 871-81	
	DI	GIUDICELLI *et al.*, "Effect of Pyrazole on ACTH Stimulated Lipolysis," *Biomedicine*, (Paris, France) (1973), 19(2), 48-51	
	DJ	HITTELMAN *et al.*, " Effects of Antilipolytic Agents and a-Adrenergic Antagonists on Cyclic AMP Metabolism in Hamster White Adipocytes," *Biochimica et Biophysica Acta*, (1973), 316(3), 403-10	
	DK	MENGEL *et al.*, "A Comparison of the Antilipolytic Effects of Nicotinic Acid, Methylisoxazole Carboxylic Acid, Methylpyrazole Carboxylic Acid and Insulin in Isolated Fat Cells,"*Pharmacology*, (1972), 8(4-6), 280-90	
	DL	GIUDICELLI *et al.*, " Effect of Pyrazole on Lipolysis," *Biochemical Pharmacology*, (1972), 21(15), 2095-102	
	DM	LOTTI *et al.*, " Derivati Pirazolici Ad Attivita Ipoglicemizzante," *Farmaco, Edizione Scientifica*, (1972), 27(4), 313-16	
	DN	CARLSON *et al.*, "Potential Hypolipidemic Agents," *Acta Pharmaceutica Suecica*, (1972), 9(4), 289-304	
	DO	KRANZ *et al.*, " Pyrazolo (1.5-c)pyrimidin - ein neues heterocyclisches System," *Chemische Berichte*, (1972), 105(2), 388-405	
	DP	BIZZI *et al.*, "Some Aspects of the Effect of Nicotine on Plasma FFA and Tissue Triglycerides," *Pharmacology*, (1972), 7(4), 216-24	
	DQ	GARATTINI *et al.*, " Drugs Affecting Lipolysis," *Naunyn-Schmiedebergs Archie fuer Pharmakologie*, (1971), 269(2-4), 372-9	
	DR	BIZZI *et al.*, "Drugs lowering plasma free fatty acids: Similarities and dissimilarities with nicotinic acid effect," *Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop*, (1971), Meeting Date 1970, 207-20	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

FEB 2 2 2007
PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	DS	FROESCH *et al.*, "Effects of nicotinic acid and structurally related drugs on adipose tissue in vitro and on carbohydrate and lipid metabolism of normal and diabetic rats in vivo," *Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop*, (1971), Meeting Date 1970, 773-94	
	DT	BUTCHER, "Effects of nicotinic acid on cyclic AMP levels in rat adipose tissue," *Metab. Eff. Nicotinic Acid Its Deriv., Proc. Workshop*, (1971), Meeting Date 1970, 347-55	
	DU	GARATTINI *et al.*, " Nuove prospettive per il controllo farmacologico dei trigliceridi ematici," *Minerva Medica*, (1971), 62(72), 3431-2	
	DV	MALAISSE *et al.*, "Biochemical, Pharmacological, and Physiological Aspects of the Adenylcyclase-Phosphodiesterase System in the Pancreatic β-Cells," *Struct. Metab. Pancreatic Islets, Proc. Int. Symp.*, (1970), Meeting Date 1969, 435-44	
	DW	TAMASI *et al.*, "Changes in serum triglyceride and cholesterol levels independently of free fatty acid after lipolysis inhibitors," *Biochemical Pharmacology*, (1970), 19(5), 1826-30	
	DX	CARMENA *et al.*, "Effect of 5-mthylpyrazole-3-carboxylic acid on plasma free fatty acids and blood sugar in geese," *Biochemical Pharmacology*, (1970), 19(5), 1838-40	
	DY	LUYCKX *et al.*, "Facteurs influencant la secretion de glucagon pancreatique et extrapancreatique," *Acta Isotopica*, (1970), 10(3-4), 269-84	
	DZ	KUPIECKI *et al.*, "Stimulation of lipolysis in adipose tissue in vitro by inhibitors of lipid mobilization," *Journal of Lipid Research*, (1970), 11(1), 38-41	
	EA	HAVEL *et al.*, " Effects of 5-methylpyrazole-3- carboxylic acid (MPCA) on fat mobilization, ketogenesis and glucose metabolism during exercise in man," *Advan. Exp. Med. Biol.*, (1969), 4 105-15	
	EB	TAMASI *et al.*, "Szabadzsirsav-csokkento vegyuletek hatasa alloxan-diabeteses patkanyokon," *Kiserletes Orvostudomany*, (1969), 21(3), 259-63	
	EC	EASTWOOD *et al.*, " Some effects of 3-chloroisoxazole-5-carboxylic acid on lipid and carbohydrate metabolism," *Biochemical Pharmacology*, (1969), 18(3), 569-77	
	ED	BIZZI *et al.*, "The hypersensitivity of adipose tissue to norepinephrine and other lipolytic agents during blockade of free fatty acids (FFA) mobilization, " *Biochemical Pharmacology*, (1969), 18(9), 2053-60	
	EE	TAMASI *et al.*, "Comparison of the Antilipemic Effect of Nicotinic Acid (NA) and 3-Methylpyrazole-5-Carboxylic Acid (MPC) in rats," *Biochemical Pharmacology*, (1968), 17(9), 1789-94	
	EF	BIZZI *et al.*, "Different responses of white and brown adipose tissue to drugs affecting lipolysis," *Biochemical Pharmacology*, (1968), 17(12), 2407-12	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	EG	KUPIECKI *et al.*, "Effects of 5-Methylpyrazole-3-carboxylic acid (U-19425) and nicotinic acid on lipolysis in vitro and in vivo and on cyclic-3',5'-AMP phosphodiesterase," *Journal of Pharmacology and Experimental Therapeutics,* (1968), 160(1), 166-70	
	EH	SICKINGER, "Glucose requirement for prolonged blocking of lipolysis with 3,5-dimethylisoxazole and 5-methylpyrazole-3-carboxylic acid," *Klinische Wochenschrift*, (1968), 46(10), 563-5	
	EI	BIZZI, "Inhibition of fatty acid release by pyrazole derivatives," *Progress in Biochemical Pharmacology*, (1968), 4 573-7	
	EJ	FANG, "Salicylate hypoglycemic action in alloxan-diabetic rats and structural relationships," *Archives Internationales de Pharmacodynamie et de Therapie,* (1968), 176(1), 193-208	
	EK	TAMASI *et al.*, "3-(5)-Metil-5-(3)-pirazol-karbonsav (MPK) patkanyok alloxan-diabeteses lipaemiajara gyakorolt hatasa," *Acta Pharmaceutica Hungarica*, (1968), 38(2-3), 166-70	
	EL	BIZZI *et al.*, "3-Methyl-5-Carboxamidepyrazole, a long lasting inhibitor of lipolysis," *Farmaco, Edizione Scientifica*, (1967), 22(9), 709-16	
	EM	SMITH *et al.*, "Absorbtion, Metabolism, and Excretion of 5-Methylpyrazole-3-carboxylic Acid in the Rat, Dog, and Human," *Journal of Pharmaceutical Sciences*, (1967), 56(9), 1150-7	
	EN	GERRITSEN *et al.*, "Development of Tachyphylaxis to the Antilipolytic, Hypoglycemic Agent, 5-Methylpyrazole-3-carboxylic Acid, U-19425," *Proceedings of the Society for Experimental Biology and Medicine,* (1967), 126(2), 524-9	
	EO	HOLLOBAUGH *et al.*, "The Effect of a Pyrazole Derivative on Plasma Free Fatty Acids In Man," *Metabolism: Clinical and Experimental*, (1967), 16(11), 996-1000	
	EP	TAMASI *et al.*, "Effects of 3-Carboxyl-5-Methylpyrazole (CMP) on Serum and Liver Lipids in Rats," *Medicina et Pharmacologia Experimentalis,* (1967), 16(6), 573-8	
	EQ	HO *et al.*, "Insulin-Like Action of Quabain I. Effect on Carbohydrate Metabolism," *Biochimica et Biophysica Acta,* (1967), 144(1), 61-73	
	ER	SPRIO *et al.*, "Transformazioni nucleari per idrogenolisi. Transformazione del nucleo isossiazolico in nucleo piridazinico," *Annali di Chimica*, (Rome, Italy) (1967), 57(7), 846-54	
	ES	BIZZI *et al.*, "Lowering of plasma triglycerides as a result of a decreased free fatty acid mobilization," *Journal of Pharmacy and Pharmacology,* (1966), 18(9), 611-14	
	ET	HABRAKEN *et al.*, "Pyrazoles II. Ionisation constants of pyrazolecarboxylic and pyrazoleacetic acids," *Recueil des Travaux Chimiques des Pays-Bas,* (1966), 85(11), 1194-6	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	EU	VETULANI, "The metabolic activity of some isoxazole and pyrazole derivatives," *Dissertationes Pharmaceuticae et Pharmacologicae*, (1966), 18(6), 573-84	
	EV	SMITH *et al.*, "5-Methylpyrazole-3-carboxylic Acid. The Potent Hypoglycemic Metabolite of 3,5-Dimethylpyrazole in the Rat," *Journal of Medicinal Chemistry*, (1965), 8(3), 350-3	
	EW	TABAK *et al.*, "Chromatography of Pyrazole Derivatives on Acetylated Paper," *Journal of Chromatography*, (1965), 17(3), 520-7	
	EX	FROESCH *et al*, "Insulin Inhibition of Spontaneous Adipose Tissue Lipolysis and Effects upon Fructose and Glucose Metabolism," *Molecular Pharmacology*, (1965), 1(3), 280-96	
	EY	SMITH *et al.*, "Metabolism of 3,5-dimethylpyrazole-C^{14} in the rat," *Journal of Pharmacology and Experimental Therapeutics*, (1965), 150(2), 316-21	
	EZ	HAMLIN *et al.*, " Relationship between in vitro dissolution rates and solubilities of numerous compounds representative of various chemical species," *Journal of Pharmaceutical Sciences*, (1965), 54(11), 1651-3	
	FA	GERRITSEN *et al.*, "The effect of 5-Methylpyrazole-3-Carboxylic Acid on Carbohydrate and Free Fatty Acid Metabolism," *Journal of Pharmacology and Experimental Therapeutics*, (1965), 150(3), 491-8	
	FB	MARSHUPTA *et al.*, "The solubility of propylene in aromatic hydrocarbons," *Khim. Prom.*, (1965), 41(8), 585-7	
	FC	RINGEL *et al.*, "Darstellung and Aminolyse des 1,1,1-Trichloracetylacetons," *Journal fuer Praktische Chemie*, (Leipzig) (1964), 26(5-6), 333-9	
	FD	GRANDBERG, "Pyrazoles XXXIV. Ultraviolet Spectra of Pyrazole Systems," *Zhurnal Obshchei Khimii*, (1963), 33 519-25	
	FE	TABAK *et al.*, "Investigation of Pyrazoles XXV. Paper Chromatography of Pyrazolecarboxylic Acids," *Zhurnal Obshchei Khimii*, (1962), 32 1562-4	
	FF	HOPFF *et al.*, "Uber Decarboxylierung und Dissoziation heterocyclischer Dicarbonsauren," *Helvetica Chimica Acta*, (1961), 44 1058-63	
	FG	D'AGOSTINO *et al.*, "Reducing activity in vitro of certain antibiotic and chemotherapeutic drugs," *Aggiorn. Pediat.*, (1961), 12(10), 477-84	
	FH	TERENT'EV *et al.*, "Pyrazoles IX. New Method of Synthesizing Pyrazolecarboxylic Acids," *Zhurnal Obshchei Khimii*, (1960), 30 2925-31	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	FI	DAL MONTE *et al.*, "Ricerche sugli eterociclici: spettri di assorbimento U.V. e proprieta cromoforiche," *Gazzetta Chimica Italiana.* (1956), 86 797-848	
	FJ	DAL MONTE *et al.*, "Ricerche nella serie dei pirazoli: Spettri U.V. di alcuni metal-, carbossi- e fenil-pirazoli," *Bollettino Scientifico della Facolta di Chimica Industriale di Bologna*, (1954), 12 147-9	
	FK	AINSWORTH *et al.*, "Reactions of Hydrazines with γ-pyrones," *Journal of the American Chemical Society*, (1954), 76, 3172-4	
	FL	LLOYD *et al.*, "The Dissociation Constants of Cupric Salts of Some Monocarboxylic Acids," *Journal of the Chemical Society*, (1951), 1786-9	
	FM	PINO, " Le Costanti di dissociazione di alcuni derivati della serie del pirazolo e dell' isossazolo," *Annali di Chimica*, (Rome, Italy) (1950), 40 575-92	
	FN	HENRY *et al.*, "Aromatic Isocyanates as Reagents for the Identification of Some Heterocyclic Compounds," *Journal of the American Chemical Society*, (1949), 71, 2297-2300	
	FO	HUTTEL *et al.*, " Uber die Loslichkeit der Pyrazol-und Triazolaldehyde in Alkalien," *Ann.*, (1947), 558, 34-47	
	FP	MUSANTE *et al.*, "La degradazione di Curtius applicata ad alcuni acidi pirazolcarbonici," *Gazzetta Chimica Italiana*, (1947), 77, 182-98	
	FQ	MUSANTE, "Su alcuni acidi pirazolcarbonici e loro derivati," *Gazzetta Chimica Italiana*, (1945), 75, 121-36	
	FR	DEWAR *et al.*, "Sulphanilamides of Some Aminopyrazoles, and a Note on the Application of *p*-Phthalimidobenzenesulphonyl Chloride to the Synthesis of Sulphanilamides," *Journal of the Chemical Society*, (1945), 114-16	
	FS	LANGLEY *et al.*, "Solubility of the Flavianates of Certain Organic Bases in Water, Ethanol, and *n*-Butanol at 3 and 30°," *Journal of the American Chemical Society*, (1942), 64, 2507-8	
	FT	CUSMANO, "Transformation di acidi γ-isossiazolcarbonici in derivati del pirazolo," *Gazzetta Chimica Italiana*, (1940), 70, 235-40	
	FU	AUWERS *et al.*, "Uber Acyl-pyrazole," *Journal fuer Praktische Chemie*, (Leipzig) (1930), 126 146-76	
	FV	SAGI *et al.*, "Studies on the Metabolism of Azolecarboxylic Acids Closely Related to the Fusaric Acid (5-Butylpyridine-2-carboxylic Acid)," *Yakugaku Zasshi*, (1988), 108(4), 350-4	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59.US2. PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	FW	YAMANAKA *et al.*, " Sytheses of Heteroaromatic Carboxylic Acids Closely Related to Fusaric Acid," *Chemical & Pharmaceutical Bulletin*, (1983), 31(12), 4549-53	
	FX	KESKIN, "Semikarbazid'in α,γ-diketoasitler ve bunlarin etil esterleri uzerine etkimesi," *Rev. faculte Sci. Univ. Istanbul*,(1944), 9A, 81-9	
	FY	HUO *et al.*, "Methyl 4-bromo-1,3-dimethylpyrazole-5-carboxylate," *Acta Crystallographica, Section E: Structure Reports Online*, (2003), E59(12), o2013-o2014	
	FZ	EHLERT *et al.*, "Polynuclear pyrazolate complexes of copper. Crystal and molecular structures of...," *Canadian Journal of Chemistry*, (1992), 70(8), 2161-73	
	GA	ROJAHN *et al.*, "Beitrag zur Kenntnis der Rosenmundschen Aldehydsynthese im heterocyclischen system," *Arch. Pharm.*, (1926), 264, 337-47	
	GB	MORGAN *et al.*, "CLII.- Substitution in the Pyrazole Series. Halogen Derivatives of 3 : 5-Dimethylpyrazole," *Journal of the Chemical Society, Transactions*, (1923), 123 1308-18	
	GC	BANKS *et al.*, "Fluorocarbon Derivatives of Nitrogen. Part 8. Reactions Between Heteroaromatic *N*-Imines (*N*-Iminopyridinium and *N*-Iminoquinolinium Ylide) and Perfluoropropene,2*H*-Pentafluoropropene, Perfluorobut-2-ene, Perfluoro-(2-methylpent-2-ene), Perfluorobut-2-yne, and Perfluoropyridine: Synthesis of Fluorinated 3-Azaindolizines (Pyrazolo[1,5-a]-pyridines)," *Journal of the Chemical Society, Perkin Transactions 1*, (1982), (7), 1593-600	
	GD	FROESCH *et al.*, Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. I. Inhibition of lipolysis, effects on glucose, fructose, and glycogen metabolism in vitro and comparison with insulin. *Molecular Pharmacol.* (1967), 3(5), 429-41	
	GE	MUGNAINI *et al.*, Heterocyclic syntheses with propargyl alcohol and butynediol. II. *Classe sci. fis., mat. e nat.* (1953), 14, 275-80	
	GF	MUGNAINI *et al.*, Heterocyclic syntheses with propargyl alcohol and butynediol. *Classe sci. fis., mat. e nat.* (1953), 14, 95-8	
	GG	HÜTTEL Über einige Aldehyde der Pyrazol- und der 1.2.3-Triazol-Reihe. *Berichte der deutschen chemischen Gesellschaft (A and B Series)* 74(10), 1941, 1680-1687	
	GH	PANIZZI *et al.*, Heterocyclic syntheses. VII. Some pyrazolic ketones. *Gazzetta Chimica Italiana* (1946), 76, 66-77	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 11 | of | 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59. US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	GI	MELANI *et al.*, Synthesis of 5*H*-10,11-dihydropyrazolo[5,1-c][1,4]benzodiazepine derivatives. II. *Journal of Heterocyclic Chemistry* (1984), 21(3), 813-15	
	GJ	KLAGES *et al.*, Pyrazoles from 1:3-diketones and alkyl diazoacetates. *Journal fuer Praktische Chemie* (1902), 65(ii), 387-93	
	GK	OWEN *et al.*, Olefinic acids. II. Reactivity of α-bromoacrylic acid and some related compounds. *Journal of the Chemical Society* (1947), 1030-4	
	GL	ABDALLAH *et al.*, Diazoacetaldehyde dimethyl acetal: a new route to cyclopropane aldehydes and formylpyrazoles. *Tetrahedron Letters* (1980), 21(23), 2239-42	
	GM	International Search Report, WO 2005/011677, 12/10/2004	
	GN	ALTSCHUL *et al.*, Influence of nicotinic acid on serum cholesterol in man. *Archives of biochemistry* (1955), 54(2), 558-9	
	GO	TAVINTHARAN *et al.*, The benefits of niacin in atherosclerosis. *Current atherosclerosis reports* (2001), 3(1), 74-82	
	GP	CARLSON *et al.*, Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. *Journal of Internal Medicine* (2005), 258(2), 94-114	
	GQ	LORENZEN *et al.*, Characterization of a G protein-coupled receptor for nicotinic acid. *Molecular Pharmacology* (2001), 59(2), 349-357	
	GR	SOGA *et al.*, Molecular identification of nicotinic acid receptor. *Biochemical and Biophysical Research Communications* (2003), 303(1), 364-369	
	GS	TUNARU *et al.*, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. *Nature Medicine* (New York, NY, United States) (2003), 9(3), 352-355	
	GT	ZHANG *et al.*, Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. *Biochemical and Biophysical Research Communications* (2005), 334(2), 729-732	
	GU	BENYO *et al.*, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. *Journal of Clinical Investigation* (2005), 115(12), 3634-3640	
	GV	O'KANE *et al.*, A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. *British journal of clinical pharmacology* (1992), 33(4), 451-3	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59. US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	GW	JIRKOVSKY *et al.*, Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids. *Journal of Medicinal Chemistry* (1982), 25(10), 1154-6	
	GX	HUNNINGHAKE *et al.*, Controlled trial of acifran in type II hyperlipoproteinemia. *Clinical pharmacology and therapeutics* (1985), 38(3), 313-7	
	GY	SEKI *et al.*, Studies on hypolipidemic agents. II. Synthesis and pharmacological properties of alkylpyrazole derivatives. *Chemical & Pharmaceutical Bulletin* (1984), 32(4), 1568-77	
	GZ	VAN HERK *et al.*, Pyrazole Derivatives as Partial Agonists for the Nicotinic Acid Receptor. *Journal of Medicinal Chemistry* (2003), 46(18), 3945-3951	
	HA	MAHBOUBI *et al.*, Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74. *Biochemical and Biophysical Research Communications* (2006), 340(2), 482-490	
	HB	FROESCH *et al.*, Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. II. Antilipolytic and hypoglycemic effects in vivo. *Molecular Pharmacol.* (1967), 3(5), 442-52	
	HC	Beilstein Records (BRN): 10958, Chemical Name (CN):4-methyl-5-propionyl-1(2)*H*-pyrazole-3-carboxylic acid	
	HD	Beilstein Records (BRN): 14055, Chemical Name (CN): 4-methyl-5-propionyl-1(2)*H*-pyrazole-3-carboxylic acid ethyl ester	
	HE	GERRITSEN *et al.*, Effects of 5-methylpyrazole-3-carboxylic acid, U-19425, on FFA [free fatty acid] mobilization. *Advan. Exp. Med. Biol.* (1969), 4 93-103	
	HF	BIZZI *et al.*, Correlation between the effect of drugs on plasma free fatty acids and on tissue triglycerides. *Advan. Exp. Med. Biol.* (1969), 4 201-11	
	HG	GUNDERSEN *et al.*, Effects of 5-methylpyrazole-3-carboxylic and (U-19,425) and nicotinic acid (NA) on free fatty acids (FFA), triglycerides (TG), and cholesterol in man. *Advan. Exp. Med. Biol.* (1969), 4, 213-26	
	HH	KIENER, Enzymic oxidation of methyl groups in heteroarenes: a versatile method for the preparation of heteroaromatic carborylic acids. *Angew. Chem., Int. Ed. Engl.*, 1992, 31(6), 774-5	
	HI	AKTORIES *et al.*, Inhibition of adenylate cyclase and stimulation of a high affinity GTPase by the antilipolytic agents, nicotinic acid, acipimox and various related compounds. *Arzneimittel-Forschung* (1983), 33(11), 1525-7	
	HJ	PRYOR *et al.*, Purification of maize alcohol dehydrogenase and competitive inhibition by pyrazoles. *Biochemistry International* (1982), 4(4), 431-8	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59. US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	HK	BIZZI *et al.*, Effects of antilipolytic agents on glucose utilization by adipose tissue. *Biochemical Pharmacology* (1973), 22(6), 763-8	
	HL	MYLES *et al.*, The development of tolerance to antilipolytic agents in rats. *Biochemical Pharmacology* (1985), 34(2), 269-74	
	HM	STRATTON *et al.*, The development of tolerance to antilipolytic agents by isolated rat adipocytes. *Biochemical Pharmacology* (1985), 34(2), 275-9	
	HN	COTTINEAU *et al.*, Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids. *Bioorganic & Medicinal Chemistry Letters* (2002), 12(16), 2105-2108	
	HO	HAMILTON *et al.*, The inhibition of mammalian D-amino acid oxidase by metabolites and drugs. Inferences concerning physiological function. *Bioorganic Chemistry* (1982), 11(3), 350-70	
	HP	ISSEKUTZ, Effect of nicotinic acid, 5-methylpyrazole-3-carboxylic acid (U-19425), and dibutyryl cyclic AMP on renal gluconeogenesis. *Canadian Journal of Physiology and Pharmacology* (1971), 49(2), 102-5	
	HQ	REIMLINGER *et al.*, Syntheses with silver or sodium pyrazoles. II. Reactions of the silver salts of methylpyrazoles with halogens. *Chemische Berichte* (1970), 103(6), 1949-53	
	HR	SEKIHACHI *et al.*, Synthesis and chromophoric properties of symmetrical bis-heteroannelated diketopiperazines: diimidazo- and dipyrazolo-piperazinediones. *Dyes and Pigments* (1996), 32(1), 43-58	
	HS	TIHANYI *et al.*, Pyrazolecarboxylic acid hydrazides as antiinflammatory agents. New selective lipoxygenase inhibitors. *European Journal of Medicinal Chemistry* (1984), 19(5), 433-9	
	HT	BARALDI *et al.*, Synthesis, antibacterial activity and structure-activity relationships of N-substituted 4-diazopyrazole-5-carboxamides. 2. *Farmaco* (1991), 46(11), 1337-50	
	HU	ALBERTI *et al.*, Alkylpyrazoles. *Farmaco, Edizione Scientifica* (1961), 16 527-39	
	HV	ALEMAGNA *et al.*, Pyrazole synthesis from α-dicarbonyl compounds. *Gazzetta Chimica Italiana* (1963), 93(6), 748-56	
	HW	INFANTES *et al.*, Packing modes in eight 3-ethoxycarbonylpyrazole derivatives. Influence of the substituents on the crystal structure and annular tautomerism. *Heterocycles* (1999), 50(1), 227-242	
	HX	BERINGER *et al.*, Attempts towards oral diabetes therapy by means of inhibition of lipolysis with 5-methylpyrazole-3-carbonic acid. *Hormone and Metabolic Research* (1970), 2(2), 81-5	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59. US2.PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	HY	MISHRA *et al.*, A heteroaromatic acid from marine sponge Suberites vestigium. *Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry* (1998), 37B(2), 199-200	
	HZ	BANKS, Selectfluor reagent F-TEDA-BF4 in action: tamed fluorine at your service. *Journal of Fluorine Chemistry* (1998), 87(1), 1-17	
	IA	MIETHCHEN *et al.*, Micelle-activated reactions. I. Micelle-activated iodination and partial dehalogenation of pyrazoles and 1,2,4-triazoles. *Journal fuer Praktische Chemie* (Leipzig) (1989), 331(5), 799-805	
	IB	SAHA *et al.*, Mixed-ligand complexes of cobalt(II) and nickel(II) with 1-hydroxymethyl-5(3)-methylpyrazole-3(5)-carboxylic acid and heterocyclic amines. *Journal of the Indian Chemical Society* (1985), 62(2), 96-9	
	IC	SAHA *et al.*, Synthesis, characterization and coordinating properties of a new benzimidazolylpyrazole: cobalt(II), nickel(II) and copper(II) complexes of 5-methyl-3-(2'-benzimidazolyl)pyrazole. *Journal of the Indian Chemical Society* (1993), 70(11-12), 1035-42	
	ID	PARAMESWARAN *et al.*, Secondary metabolites from the sponge Tedania anhelans: isolation and characterization of two novel pyrazole acids and other metabolites. *Journal of Natural Products* (1997), 60(8), 802-803	
	IE	MANAEV *et al.*, Dimethylpyrazole-based syntheses. V. Nitration of 4-halopyrazole-3- and 5-carboxylic acids. *Zhurnal Obshchei Khimii* (1982), 52(11), 2592-8	
	IF	AKTORIES *et al.*, Stimulation of a low Km GTPase by inhibitors of adipocyte adenylate cyclase. *Molecular Pharmacology* (1982), 21(2), 336-42	
	IG	AKTORIES *et al.*, In vivo and in vitro desensitization of nicotinic acid-induced adipocyte adenylate cyclase inhibition. *Naunyn-Schmiedeberg's Archives of Pharmacology* (1982), 318(3), 241-5	
	IH	FRANCESCHI *et al.*, Synthesis and aggregation of two-headed surfactants bearing amino acid moieties. *New Journal of Chemistry* (1999), 23(4), 447-452	
	II	OGAWA *et al.*, Identification of metabolites of the acaricide, tebufenpyrad, formed in in vivo and in vitro systems of rats. *Nippon Noyaku Gakkaishi* (1994), 19(3), 169-79	
	IJ	TAKASAKI *et al.*, Hypoglycemic activity of certain heterocyclic acid derivatives. *Nippon Yakurigaku Zasshi* (1973), 69(6), 977-94	
	IK	CABILDO *et al.*, Carbon-13 NMR chemical shifts of N-unsubstituted and N-methylpyrazole derivatives. *Organic Magnetic Resonance* (1984), 22(9), 603-7	
	IL	SAHA *et al.*, Design, synthesis and spectroscopic characterization of palladium(II) and platinum(II) complexes of pyrazole-derived ligands with potential anti-tumor properties in its historical perspective. *Polyhedron* (1994), 13(13), 2025-33	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 15

Complete if Known	
Application Number	10/560,332
Filing Date	09/08/2006
First Named Inventor	Graeme Semple
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	59. US2.PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	IM	KOJIMA *et al.*, Renal excretion of sodium 4-iodo-5-methylpyrazole-3-carboxylate-131I. *Radioisotopes* (1979), 28(5), 300-5	
	IN	BARALDI *et al.*, An efficient procedure for the synthesis of 5H-6-substituted pyrazolo[1,5-d]-1,2,4-triazine-4,7-diones. *Synthesis* (1999), (3), 453-458	
	IO	FLORES *et al.*, Synthesis of hydroxypyrazoles and 1-methyl-3-isoxazolones via haloform reactions. *Tetrahedron Letters* (2002), 43(28), 5005-5008	
	IP	PIKE *et al.*, Identification of a nicotinic acid receptor: Is this the molecular target for the oldest lipid-lowering drug? *Current Opinion in Investigational Drugs* (Thomson Scientific) (2004), 5(3), 271-275	
	IQ	OFFERMANNS, The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. *Trends in Pharmacological Sciences* (2006), 27(7), 384-390	
	IR	BARIANA *et al.*, Nicotinic acid esters as coronary vasodilators. *Journal of Medicinal Chemistry* (1971), 14(4), 372-3	
	IS	HOLLAND *et al.*, Heterocyclic tetrazoles, a new class of lipolysis inhibitors. *Journal of Medicinal Chemistry* (1967), 10(2), 149-54	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.